Nektar Therapeutics (NKTR) Cost of Revenue (2010 - 2026)

Nektar Therapeutics' Cost of Revenue history runs 17 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 55.38% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at -$30.2 million (down 175.37% YoY), while the FY2024 annual figure was $42.0 million, up 24.52% from the prior year.
• Cost of Revenue was $7.7 million for Q1 2026 at Nektar Therapeutics, up from -$37.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $17.3 million in Q1 2025 to a low of -$37.9 million in Q4 2025.
• Historically, Cost of Revenue has averaged $5.1 million across 5 years, with a median of $7.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue surged 150.02% in 2023, then sank 540.22% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $6.2 million in 2022, then grew by 16.85% to $7.3 million in 2023, then climbed by 18.15% to $8.6 million in 2024, then tumbled by 540.22% to -$37.9 million in 2025, then surged by 120.33% to $7.7 million in 2026.
• The last three Cost of Revenue figures came in at $7.7 million (Q1 2026), -$37.9 million (Q4 2025), and $17.3 million (Q1 2025), per Business Quant data.